Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) has issued an announcement.
On January 14, 2025, Pulse Biosciences, Inc. announced that it had posted an updated investor presentation on its website, detailing recent progress in its ongoing product development programs for the nPulse Vybrance Percutaneous Electrode, the nPulse Cardiac Clamp and the nPulse Cardiac Catheter. The investor deck, dated as of January 2026, is intended for use in communications with investors and analysts and underscores the company’s efforts to advance and showcase its cardiac-focused technology pipeline, offering stakeholders a consolidated view of its development trajectory while emphasizing that the materials are summary in nature and subject to standard securities law limitations on liability and updating obligations.
The most recent analyst rating on (PLSE) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held down primarily by very weak financial performance (minimal revenue, negative gross profit, and heavy ongoing cash burn). Offsetting this, technical indicators suggest near-term stabilization, and the latest earnings call points to meaningful clinical/regulatory progress and early commercial traction, though losses and spending remain elevated. Valuation is constrained by negative earnings and no dividend yield data.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a Delaware-incorporated medical technology company focused on developing proprietary nPulse-based devices, including percutaneous electrodes, cardiac clamps and cardiac catheters, targeting interventional and cardiac procedure markets.
Average Trading Volume: 169,475
Technical Sentiment Signal: Hold
Current Market Cap: $987.4M
For detailed information about PLSE stock, go to TipRanks’ Stock Analysis page.